Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.

European urology - 1 Mar 2020

Reimers Melissa A, Yip Steven M, Zhang Li, Cieslik Marcin, Dhawan Mallika, Montgomery Bruce, Wyatt Alexander W, Chi Kim N, Small Eric J, Chinnaiyan Arul M, Alva Ajjai S, Feng Felix Y, Chou Jonathan

Abstract excerpt

BACKGROUND: Cyclin-dependent kinase 12 (CDK12) loss occurs in 3-7% of metastatic prostate cancer patients and is characterized by a genomic instability signature, but the clinical implications of CDK12 loss are not well established. OBJECTIVE: To determine the clinical course of patients with CDK12 mutant advanced prostate cancer compared with other genomic subtypes. DESIGN, SETTING, AND PARTICIPANTS: A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cyclin-Dependent Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Staging

Share to Prostatic Neoplasms

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 31640893
DOI: 10.1016/j.eururo.2019.09.036
PMCID: PMC7365609

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.PMID 31640893Read ↗

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.Semantic proximity Read ↗

Prognostic value of genomic mutations in metastatic prostate cancerSemantic proximity Read ↗

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.Semantic proximity Read ↗

An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.Semantic proximity Read ↗

Characterizing CDK12-Mutated Prostate CancersSemantic proximity Read ↗

Genomics of lethal prostate cancer at diagnosis and castration resistanceSemantic proximity Read ↗

Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.Semantic proximity Read ↗

Characteristics of BRCA2 Mutated Prostate Cancer at Presentation.Semantic proximity Read ↗

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.Semantic proximity Read ↗

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerSemantic proximity Read ↗

Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis.Semantic proximity Read ↗

Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.